 | |
| Company type | Public |
|---|---|
| Industry | Healthcare |
| Founded | 2005 |
| Headquarters | Boston, United States |
Key people | Christopher Viehbacher (
Chairman) Daphne Zohar ( CEO) |
| Products | Medicines |
| Revenue | 
$3.3 million (2023)
[1] |
 $(146.2) million (2023)
[1] | |
| $(66.6) million (2023)
[1] | |
| Website |
puretechhealth |
PureTech Health is a biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
History
The company was founded by Daphne Zohar, an American entrepreneur, in 2005. [2] It was the subject of an initial public offering on the London Stock Exchange in June 2015. [3]
Operations
Companies which PureTech Health founded include Karuna Pharmaceuticals, [4] Gelesis, which has received FDA approval as a treatment for weight management, [5] Akili Interactive Labs, which is developing a digital therapeutic platform for cognitive disorders, [6] Vedanta Biosciences, which is developing drugs to treat autoimmune and inflammatory diseases, [7] and Follica which is developing new treatments for androgentic alopecia among others. [8] PureTech also has a pipeline of its own immunology, lymphatic and oncology based therapeutics. [9]
References
- ^ a b c "Annual Results 2023". PureTech Health. Retrieved 26 April 2024.
- ^ "PureTech's long view on biopharma". Boston Globe. 26 August 2015. Archived from the original on 16 August 2019. Retrieved 16 August 2019.
- ^ "PureTech banks $171M in a London IPO to fund its biotech bets". Fierce Biotech. 19 June 2015. Archived from the original on 16 August 2019. Retrieved 16 August 2019.
- ^ "PureTech Health surges as Karuna investment rockets 442%". Proactive Investors. 19 November 2019. Archived from the original on 14 December 2019. Retrieved 14 December 2019.
- ^ "Gelesis raises $12 million for pill that staves off hunger". BetaBoston.com. May 16, 2014. Archived from the original on August 3, 2014. Retrieved December 14, 2019.
- ^ "Akili Interactive adds $13 million to Series C funding pool". The Pharma Letter. 9 August 2018. Archived from the original on 14 December 2019. Retrieved 14 December 2019.
- ^ "PureTech Health affiliate Vedanta Biosciences awarded $5.8m grant". Sharecast. 5 December 2019. Archived from the original on 14 December 2019. Retrieved 14 December 2019.
- ^ "Positive Results From PureTech Affiliate Male Pattern Hair Loss Study". Morning Star. 13 June 2019. Archived from the original on 1 March 2020. Retrieved 14 December 2019.
- ^ "PureTech Licenses Glyph Lymphatic Technology". FT. 29 August 2017. Archived from the original on 15 January 2020. Retrieved 14 December 2019.
External links
|
| |
| Company type | Public |
|---|---|
| Industry | Healthcare |
| Founded | 2005 |
| Headquarters | Boston, United States |
Key people | Christopher Viehbacher (
Chairman) Daphne Zohar ( CEO) |
| Products | Medicines |
| Revenue |
$3.3 million (2023)
[1] |
| $(146.2) million (2023)
[1] | |
| $(66.6) million (2023)
[1] | |
| Website |
puretechhealth |
PureTech Health is a biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
History
The company was founded by Daphne Zohar, an American entrepreneur, in 2005. [2] It was the subject of an initial public offering on the London Stock Exchange in June 2015. [3]
Operations
Companies which PureTech Health founded include Karuna Pharmaceuticals, [4] Gelesis, which has received FDA approval as a treatment for weight management, [5] Akili Interactive Labs, which is developing a digital therapeutic platform for cognitive disorders, [6] Vedanta Biosciences, which is developing drugs to treat autoimmune and inflammatory diseases, [7] and Follica which is developing new treatments for androgentic alopecia among others. [8] PureTech also has a pipeline of its own immunology, lymphatic and oncology based therapeutics. [9]
References
- ^ a b c "Annual Results 2023". PureTech Health. Retrieved 26 April 2024.
- ^ "PureTech's long view on biopharma". Boston Globe. 26 August 2015. Archived from the original on 16 August 2019. Retrieved 16 August 2019.
- ^ "PureTech banks $171M in a London IPO to fund its biotech bets". Fierce Biotech. 19 June 2015. Archived from the original on 16 August 2019. Retrieved 16 August 2019.
- ^ "PureTech Health surges as Karuna investment rockets 442%". Proactive Investors. 19 November 2019. Archived from the original on 14 December 2019. Retrieved 14 December 2019.
- ^ "Gelesis raises $12 million for pill that staves off hunger". BetaBoston.com. May 16, 2014. Archived from the original on August 3, 2014. Retrieved December 14, 2019.
- ^ "Akili Interactive adds $13 million to Series C funding pool". The Pharma Letter. 9 August 2018. Archived from the original on 14 December 2019. Retrieved 14 December 2019.
- ^ "PureTech Health affiliate Vedanta Biosciences awarded $5.8m grant". Sharecast. 5 December 2019. Archived from the original on 14 December 2019. Retrieved 14 December 2019.
- ^ "Positive Results From PureTech Affiliate Male Pattern Hair Loss Study". Morning Star. 13 June 2019. Archived from the original on 1 March 2020. Retrieved 14 December 2019.
- ^ "PureTech Licenses Glyph Lymphatic Technology". FT. 29 August 2017. Archived from the original on 15 January 2020. Retrieved 14 December 2019.